Literature DB >> 21356232

ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD.

Jean-G Gehricke1, Nuong Hong, Timothy L Wigal, Vivien Chan, Ashley Doan.   

Abstract

Individuals with ADHD may self-medicate with nicotine, the main psychoactive ingredient in tobacco smoke, in order to reduce symptoms and negative moods associated with ADHD. ADHD medication (e.g., methylphenidate and atomoxetine) may mimic some of the effects of nicotine and may aid smoking cessation in smokers with ADHD. The present study examined if ADHD medication reduces smoking and withdrawal in non-treatment seeking smokers with ADHD. Fifteen adult smokers with ADHD participated in the study, which consisted of an experimental phase and field monitoring phase to examine the acute and extended effects, respectively, of ADHD medication. During the experimental phase, smokers were asked to complete a Continuous Performance Task (CPT) and the Shiffman-Jarvik smoking withdrawal questionnaire during the following four conditions: (1) ADHD medication+cigarette smoking, (2) ADHD medication+overnight abstinence, (3) placebo+cigarette smoking, and (4) placebo+overnight abstinence. During the field monitoring phase, participants were asked to provide salivary cotinine samples and complete electronic diaries about smoking, smoking urge, ADHD symptoms, and stress in everyday life for two days on ADHD medication and for two days on placebo. Results of the experimental phase showed that ADHD medication improved task performance on the CPT and reduced withdrawal during overnight abstinence. During the field monitoring phase, ADHD medication reduced salivary cotinine levels compared to placebo. In addition, the electronic diary revealed that ADHD medication improved difficulty concentrating during no smoking events and stress. The findings of the present study suggest that, along with other strategies, ADHD medication may be used to aid smoking withdrawal and cessation in smokers with ADHD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356232      PMCID: PMC3065552          DOI: 10.1016/j.pbb.2011.02.021

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  25 in total

1.  Attenuated beta endorphin response to acute stress is associated with smoking relapse.

Authors:  Darcy Shaw; Mustafa al'Absi
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

2.  Neuropsychological functioning of adults with attention deficit hyperactivity disorder.

Authors:  A J Walker; E A Shores; J N Trollor; T Lee; P S Sachdev
Journal:  J Clin Exp Neuropsychol       Date:  2000-02       Impact factor: 2.475

3.  OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences.

Authors:  Lirio S Covey; Mei-Chen Hu; Theresa Winhusen; Judith Weissman; Ivan Berlin; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2010-03-12       Impact factor: 4.492

4.  Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder.

Authors:  Jean-G Gehricke; Nuong Hong; Carol K Whalen; Kenneth Steinhoff; Timothy L Wigal
Journal:  Psychol Addict Behav       Date:  2009-12

Review 5.  Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation.

Authors:  C A Riccio; J J Waldrop; C R Reynolds; P Lowe
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

6.  Changes of the brain electrical fields during the continuous performance test in attention-deficit hyperactivity disorder-boys depending on methylphenidate medication.

Authors:  K E Zillessen; P Scheuerpflug; A J Fallgatter; W K Strik; A Warnke
Journal:  Clin Neurophysiol       Date:  2001-07       Impact factor: 3.708

7.  Which aspects of ADHD are associated with tobacco use in early adolescence?

Authors:  J D Burke; R Loeber; B B Lahey
Journal:  J Child Psychol Psychiatry       Date:  2001-05       Impact factor: 8.982

8.  Mechanisms linking socioeconomic status to smoking cessation: a structural equation modeling approach.

Authors:  Michael S Businelle; Darla E Kendzor; Lorraine R Reitzel; Tracy J Costello; Ludmila Cofta-Woerpel; Yisheng Li; Carlos A Mazas; Jennifer Irvin Vidrine; Paul M Cinciripini; Anthony J Greisinger; David W Wetter
Journal:  Health Psychol       Date:  2010-05       Impact factor: 4.267

9.  Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence.

Authors:  R Ray; M Rukstalis; C Jepson; Aa Strasser; F Patterson; K Lynch; C Lerman
Journal:  J Psychopharmacol       Date:  2008-05-30       Impact factor: 4.153

10.  Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.

Authors:  Mary Solanto; Jeffrey Newcorn; Lucia Vail; Sharone Gilbert; Iliyan Ivanov; Regina Lara
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

View more
  14 in total

1.  Prefrontal hemodynamic changes during cigarette smoking in young adult smokers with and without ADHD.

Authors:  Jean-G Gehricke; Chiara Polzonetti; Cyrus Caburian; Enrico Gratton
Journal:  Pharmacol Biochem Behav       Date:  2013-10-12       Impact factor: 3.533

2.  Increased rate of early smoking in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Laurence Jerome
Journal:  CMAJ       Date:  2017-05-29       Impact factor: 8.262

3.  D-amphetamine improves attention performance in adolescent Wistar, but not in SHR rats, in a two-choice visual discrimination task.

Authors:  Jean-Charles Bizot; Nicolas Cogrel; Fabienne Massé; Virgile Chauvin; Léa Brault; Sabrina David; Fabrice Trovero
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

4.  Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD.

Authors:  Ivan Berlin; Mei-Chen Hu; Lirio S Covey; Theresa Winhusen
Journal:  Drug Alcohol Depend       Date:  2012-02-23       Impact factor: 4.492

Review 5.  Smoking behavior characteristics of non-selected smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysis.

Authors:  Guillaume Fond; Anderson Loundou; Sebastien Guillaume; Xavier Quantin; Alexandra Macgregor; Régis Lopez; Philippe Courtet; Paquito Bernard; Daniel Bailly; Mocrane Abbar; Marion Leboyer; Laurent Boyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03-12       Impact factor: 5.270

6.  Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers.

Authors:  Sean X Luo; Lirio S Covey; Mei-Chen Hu; Frances R Levin; Edward V Nunes; Theresa M Winhusen
Journal:  Am J Addict       Date:  2015-02-06

Review 7.  The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents.

Authors:  Thomas Küpper; Jan Haavik; Hans Drexler; Josep Antoni Ramos-Quiroga; Detlef Wermelskirchen; Christin Prutz; Barbara Schauble
Journal:  Int Arch Occup Environ Health       Date:  2012-07-03       Impact factor: 3.015

8.  Ecological momentary assessment of antecedents and consequences of smoking in adults with attention-deficit/hyperactivity disorder.

Authors:  John T Mitchell; Michelle F Dennis; Joseph S English; Paul A Dennis; Amy Brightwood; Jean C Beckham; Scott H Kollins
Journal:  Subst Use Misuse       Date:  2014-05-14       Impact factor: 2.164

9.  Attention-Deficit/Hyperactivity Disorder and Nicotine Dependence in Adults.

Authors:  Bülent Bilgi; Umut Mert Aksoy; Özge Şahmelikoğlu Onur; Ayşe Fulya Maner
Journal:  Noro Psikiyatr Ars       Date:  2017-12       Impact factor: 1.339

Review 10.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.